Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Roche has reported that its majority-owned subsidiary Chugai Pharmaceutical has received approval from the Japanese Health Authority for the use of Herceptin in the early treatment for women with HER2-positive breast cancer.
Subscribe to our email newsletter
The approval was based on the impressive HERA (HERceptin Adjuvant) study results demonstrating that Herceptin significantly reduced the risk of death and recurrence by more than one third(34% and 36% respectively), in women with HER2-positive early-stage breast cancer when given following surgery and standard chemotherapy.
William Burns, CEO of Roche’s Pharmaceuticals Division, said: “It is most rewarding to see that Herceptin has improved the outlook for women with HER2-positive breast cancer in such a remarkable way and that its exceptional benefits are being recognized by health authorities across the world. We hope that all Japanese women suffering from this devastating disease will now be able to have access to Herceptin, a treatment that has been proven to offer the best chance for a cure.”